selinexor + dexamethasone + pomalidomide + bortezomib

The combination of **selinexor + dexamethasone + pomalidomide + bortezomib** is an investigational quadruplet anti-myeloma regimen studied for the treatment of relapsed or refractory multiple myeloma (RRMM)[1][3][4][10]. - **Selinexor** is a selective inhibitor of nuclear export (SINE) targeting Exportin 1 (XPO1), leading to nuclear retention and activation of tumor suppressor proteins and inhibition of oncoprotein translation[1][9]. - **Dexamethasone** is a synthetic glucocorticoid acting as an immunosuppressant and anti-inflammatory agent. - **Pomalidomide** is an immunomodulatory drug (IMiD), functioning via multiple mechanisms including modulation of cereblon, cytokine inhibition, and anti-angiogenic effects. - **Bortezomib** is a reversible proteasome inhibitor that disrupts protein degradation, leading to apoptosis in myeloma cells. This quadruplet is under clinical evaluation in heavily pretreated patients for improved efficacy, building on the effectiveness of triplet regimens. The combination aims to harness synergistic anti-myeloma effects by acting on different molecular pathways, including nuclear export, proteasome inhibition, immune modulation, and corticosteroid activity. Primary indication is relapsed/refractory multiple myeloma; development status is investigational with ongoing and reported phase I/II clinical studies[1][10].

Other names

selinexor + dexamethasone + pomalidomide + bortezomib